Cadila Healthcare Q1FY22 Earnings Results – PAT up 29% yoy at Rs 587; revenue, EBIDTA, EPS and DEBT – key highlights here

Cadila Healthcare Q1FY22 Earnings Results – Multi-national pharmaceutical company Cadila Healthcare Limited has reported a 29 per cent year-on-year (YoY) jump in its net profit at Rs 587 cr for the quarter ended 30 June 2021 on the back of a 15 per cent YOY jump in its revenue for the reporting quarter. The revenues for the April-June 2021 quarter stood at Rs 4025 cr.  

Earnings before Interest, Depreciation and Tax (EBIDTA) for the quarter was Rs 933 cr, which was up by 18 per cent y-o-y and 16 per cent on q-o-q basis. The EBIDTA margin for the quarter was 23.2 per cent, an improvement of 140 basis points on the quarter-on-quarter (q-o-q), the company said in its exchange filing. EBIDTA margin for Q1FY21 was 22.5 per cent and 21.8 per cent in Q4FY21.

See Zee Business Live TV Streaming Below:

See Key highlights here:

1. Consolidated PAT ex exceptional and one-off items at INR 587 cr up 29 per cent from Q1FY21 and up 19 per cent from Q4 FY21.
2. PAT margin for Q1 FY22 is 14.6 per cent, against 12.9 per cent in Q1FY21 and 13.4 per cent in Q4 FY21.
3. Research & Development (R&D) spend at Rs 295 crores (7.3 per cent of revenue).
4. Basic & Diluted EPS in Q1FY22 is Rs 5.74 vs Rs 4.43 in Q1 FY21.
5. Net debt as at June 30 2021 Rs 3,112 cr vs Rs 3,496 cr as at Q4FY21.
6. Net debt position as of July 31 2021 stands below Rs 1,000 cr after closure of transaction of sale and disposal of Animal Healthcare Established Markets undertaking of Zydus Animal Health and Investments Ltd.
7. Capex for Q1FY22 stood at Rs 265 cr.

On a y-o-y basis, growth in revenues was driven by strong growth in India geography partially offset by US geography, the company said in its filing to the exchanges.

Q-o-Q decline is due to process simplification and efficiency enhancement initiatives undertaken to optimize the costs.

Q4FY21 Tax expenses include benefit of Rs 218 cr on account of recognition of deferred tax asset on MAT credit of earlier years to a wholly owned subsidiary.

Shares of Cadila Healthcare today ended at Rs 562 on the NSE, down by 2.5 per cent from the last closing price on Tuesday.